ICBMT 2025

[SA01] Satellite Symposium 1 (Korea Otsuka Pharmaceutical) September 12 (Fri), 08:30-09:00		Room C
Chair(s)	Seok Lee (Ewha Womans University College of Medicine, Korea)

08:30-09:00

Ponatinib and Chemotherapy for Adult Patients with Newly Diagnosed Ph+ ALL Based on the PhALLCON Trial

Gong Benfa

Chinese Academy of Medical Sciences, China

Abstract CV

[SA02] Satellite Symposium 2 (BMS Korea) September 12 (Fri), 08:30-09:00		Room D
Chair(s)	Kyoo-Hyung Lee (Ewha Womans University College of Medicine, Korea)

08:30-09:00

Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia

Andre Schuh

University Health Network, Canada

Abstract CV

[OP05] Oral Presentation 5
Date & Time	September 12 (Fri), 09:00-10:00
Chair(s)	Ho Sup Lee (Kosin University College of Medicine, Korea) Yoon Seok Choi (Korea University College of Medicine, Korea)
Speaker(s)	09:00-09:10	Nespecabtagene Autoleucel (AT101) Demonstrates High Efficacy in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Interim Results of a Phase 2 Study Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)
	09:10-09:20	Real-World Clinical Outcomes of Tisagenlecleucel in Relapsed or Refractory DLBCL: A Single-Center Retrospective Study Gi June Min (College of Medicine, The Catholic University of Korea, Korea)
	09:20-09:30	Real-World Outcomes of Tisagenlecleucel versus Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Large B-cell Lymphomas Tong-Yoon Kim (College of Medicine, The Catholic University of Korea, Korea)
	09:30-09:40	High-Risk Extranodal NK/T-Cell Lymphoma Patients Could Benefit More from Allogeneic Hematopoietic Stem Cell Transplantation as Consolidation: A Real-World Multicenter Analysis in China Yi Xia (Peking University People's Hospital, China)
	09:40-09:50	Outcomes of Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Analysis from the Taiwan Blood and Marrow Transplantation Registry Po-Tsen Liu (College of Medicine, National Cheng Kung University, Taiwan)
	09:50-10:00	Frequency, Characteristics, Management, and Outcomes of Posttransplant Lymphoproliferative Disorders after Allogeneic HSCT in Children, 15 Years Experience: A Multicenter Study of the Turkish Pediatric Bone Marrow Transplantation Study Group Fatih Erbey (Koc University School of Medicine, Türkiye)

[OP06] Oral Presentation 6
Date & Time	September 12 (Fri), 09:00-10:00
Chair(s)	Min Kyoung Kim (Yeungnam University College of Medicine, Korea) Seong Hyun Jeong (Ajou University School of Medicine, Korea)
Speaker(s)	09:00-09:10	Impact of Donor Age on Survival Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome Dong Hyun Kim (Seoul National University College of Medicine, Korea)
	09:10-09:20	Long-Term Outcomes and Prognostic Factors Following Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myelodysplastic Syndrome: A Nationwide Population-Based Study in Korea Eun Sang Yi (Korea University College of Medicine, Korea)
	09:20-09:30	Impact of Letermovir Prophylaxis on the Pattern of CMV Events and Its Association with Relapse in Allogenic HSCT Recipients for Myelodysplastic Syndromes Sin Young Park (Seoul National University Hospital, Korea)
	09:30-09:40	Impact of Pre-Transplant Cytoreductive Therapy on Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes with Excess of Blasts: A Retrospective Analysis Yu-eun Lee (University of Ulsan College of Medicine, Korea)
	09:40-09:50	Incidence and Risk Factors for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelofibrosis Yu-Qian Sun (Peking University People's Hospital, China)
	09:50-10:00	Association between Splenomegaly and Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis Patients So Yeon Park (College of Medicine, The Catholic University of Korea, Korea)

[OP07] Oral Presentation 7
Date & Time	September 12 (Fri), 09:00-10:00
Chair(s)	Kyoung Ha Kim (Soonchunhyang University College of Medicine, Korea) Ho-Young Yhim (Jeonbuk National University Medical School, Korea)
Speaker(s)	09:00-09:10	The Efficacy of Combination Treatment with All-Trans Retinoic Acid, Bortezomib, and Natural Killer cells on CD44-Overexpressing Myeloma Van-Tan Nguyen (Chonnam National University Medical School, Korea)
	09:10-09:20	Preclinical Study of IL-15 Armored Chimeric Antigen Receptor - Natural Killer Cells for Multiple Myeloma Ga-Young Song (Chonnam National University Medical School, Korea)
	09:20-09:30	Automated, Computational Interpretation of Multiparametric Flow Cytometry Based-Minimal Residual Disease for Multiple Myeloma (CAREMM-2401 Study) Ka Young Kim (College of Medicine, The Catholic University of Korea, Korea)
	09:30-09:40	Cost-Effectiveness of Expanding Autologous Stem Cell Transplantation Eligibility to Patients Aged 65 to 70 Years with Multiple Myeloma: A Nationwide Cohort Study in Korea Suein Choi (College of Medicine, The Catholic University of Korea, Korea)
	09:40-09:50	Retrospective Analysis of Medical Costs and Length of Initial Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation Ayako Takarada (University of Tsukuba, Japan)
	09:50-10:00	Improving Pre-Admission Readiness for HSCT Patients: Outcomes of a Structured Nursing-Led Quality Improvement Program Pei-Yu Lo (Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan)

[OP08] Oral Presentation 8
Date & Time	September 12 (Fri), 09:00-10:00
Chair(s)	Eun Sun Yoo (Ewha Womans University College of Medicine, Korea) Hye Lim Jung (Sungkyunkwan University School of Medicine, Korea)
Speaker(s)	09:00-09:10	Impact of Oral and Gut Microbiome Dysbiosis on Treatment Complications in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Suejung Jo (College of Medicine, The Catholic University of Korea, Korea)
	09:10-09:20	Hematopoietic Stem Cell Transplantation for Congenital Dyserythropoietic Anemia Jeong A Park (Inha University College of Medicine, Korea)
	09:20-09:30	Quadruple Immunotherapy for Paediatric Patients with Relapsed or Refractory Neuroblastoma Pamela Lee (The University of Hong Kong, China)
	09:30-09:40	Busulfan–Melphalan versus Carboplatin–Etoposide–Melphalan as High-Dose Chemotherapy for High-Risk Neuroblastoma in Taiwan: A Single-Center Retrospective Study Chiao-Yu Cheng (National Taiwan University Children's Hospital, Taiwan)
	09:40-09:50	Outcomes of Salvage Treatment Including High-dose Chemotherapy and Autologous Stem Cell Transplantation of Recurrent Central Nervous System Germ Cell Tumors Suhyun Yoon (University of Ulsan College of Medicine, Korea)
	09:50-10:00	Treatment Outcomes of Medulloblastoma: Efficacy of Reduced-Dose Radiotherapy, Intrathecal Methotrexate, and Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation Hee Won Cho (Sungkyunkwan University School of Medicine, Korea)

[JS03] Joint Symposium 3 (East Asia Collaborative Session): Stem Cell Transplantation in Diffuse Large B-cell Lymphoma in the Era of Immunotherapy September 12 (Fri), 10:10-11:50		Room A
Chair(s)	Je-Jung Lee (Chonnam National University Medical School, Korea) Chi-Cheng Li (Hualien Tzu Chi Hospital, Taiwan)

10:10-10:35

Optimizing Autologous Stem Cell Transplantation in the Age of CAR T-cell Therapy: Still a Standard?

Jieun Uhm

Hanyang University College of Medicine, Korea

Abstract CV
10:35-11:00

Treatment Options after CAR T-cell Failure in Diffuse Large B-cell Lymphoma

Shinichi Makita

National Cancer Center Hospital, Japan

Abstract CV
11:00-11:25

Clinical Practice and System Innovation of CAR T-Cell Therapy

Aibin Liang

Tongji Hospital Affiliated to Tongji University, China

Abstract CV
11:25-11:50

Immune Reconstitution after CAR T-cell Therapy vs. Stem Cell Transplantation: Mechanistic Insights and Clinical Implications

Tai-Chung Huang

National Taiwan University Hospital, Taiwan

Abstract CV

[SS05] Scientific Session 5 (KAICET-Cell Therapy Committee Joint Session): Next-Generation Immune Cell Therapies: From Design to Clinical Application September 12 (Fri), 10:10-11:40		Room B
Chair(s)	Kyung-Mi Lee (Korea University College of Medicine, Korea) Hyoung Jin Kang (Seoul National University College of Medicine, Korea)

10:10-10:40

Enhancing CAR-T Cell Function through Membrane-Anchored Cytokines

Hyung Cheol Kim

Curocell Inc., Korea

Abstract CV
10:40-11:10

The Mechanism of Immune Synapse Formation and Its Application to Synapse-Fortified CAR T Cells

Eun Young Choi

Seoul National University College of Medicine, Korea

Abstract CV
11:10-11:40

From Bench to Bedside: The Promise of Engineered NK Cell Therapy

Katy Rezvani

The University of Texas MD Anderson Cancer Center, USA

Abstract CV

[SS06] Scientific Session 6: GVHD Update: Evolving Paradigms in Diagnosis and Therapy September 12 (Fri), 10:10-11:40		Room C
Chair(s)	Hyeoung-Joon Kim (Chonnam National University Medical School, Korea) Hoon Kook (Chonnam National University Medical School, Korea)

10:10-10:40

Clinical Approach of GvHD Bronchiolitis Obliterans Syndrome - Early Detection, Diagnosis, Treatment

Guang-Shing Cheng

Fred Hutchinson Cancer Center, USA

Abstract CV
10:40-11:10

Novel Therapeutic Options in Chronic GVHD

Corey Cutler

Dana-Farber Cancer Institute, USA

Abstract CV
11:10-11:40

FDA-approved Therapies for Chronic GVHD

Robert Zeiser

University Medical Center Freiburg, Germany

Abstract CV

[ES02] Education Session 2: Smart Research Practices: From Data Analysis to Writing September 12 (Fri), 10:10-11:40		Room D
Chair(s)	Hawk Kim (Ewha Womans University College of Medicine, Korea) Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea)

10:10-10:40

Medical Research and Scientific Writing Using AI

Yohan Koo

CHA University, Korea

Abstract CV
10:40-11:10

Scientific Writing in BMT and Cellular Therapy Research

Mohamad Mohty

Saint-Antoine Hospital, France

Abstract CV
11:10-11:40

HSCT Research Using Easy R (EZR) Focusing on Survival Analysis

Yoshinobu Kanda

Jichi Medical University, Japan

Abstract CV

[LS05] Luncheon Symposium 5 (Novartis Korea) September 12 (Fri), 12:00-12:40		Room A
Chair(s)	Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)

12:00-12:40

Optimizing Fabhalta Therapy: Strategies and Best Practices in PNH Patients

Austin Kulasekararaj

King's College Hospital NHS Foundation Trust, UK

CV

[LS06] Luncheon Symposium 6 (Handok Inc.) September 12 (Fri), 12:00-12:40		Room B
Chair(s)	Je-Hwan Lee (University of Ulsan College of Medicine, Korea)

12:00-12:40

Optimising Transplant Potential in older AML Patients: Insights from Real-World Data

Thomas Schroeder

University Hospital Essen, Germany

Abstract CV

[LS07] Luncheon Symposium 7 (DKSH Korea) September 12 (Fri), 12:00-12:40		Room C
Chair(s)	Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)

12:00-12:40

Optimizing Neutropenia Management in Lymphoma Patients: Clinical Insights and Future Directions of G-CSF Therapy

Young Woo Jeon

College of Medicine, The Catholic University of Korea, Korea

Abstract CV

[LS08] Luncheon Symposium 8 (MSD Korea) September 12 (Fri), 12:00-12:40		Room D
Chair(s)	Yeung-Chul Mun (Ewha Womans University College of Medicine, Korea)

12:00-12:40

An Update on the Efficacy and Safety Profile of 200-day Prevymis Therapy and Q&A

Michelle Yong

Peter MacCallum Cancer Centre, Australia

Abstract CV

[SS07] Scientific Session 7: Transplantation and Relapse: Evidence and Practice Updates September 12 (Fri), 13:00-14:30		Room A
Chair(s)	Ho-Jin Shin (Pusan National University School of Medicine, Korea) Sung-Yong Kim (Konkuk University School of Medicine, Korea)

13:00-13:30

Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia

Partow Kebriaei

The University of Texas MD Anderson Cancer Center, USA

Abstract CV
13:30-14:00

Role of MRD Monitoring and Maintenance Therapy after HSCT in TP53 altered AML or MDS

David Sallman

H. Lee Moffitt Cancer Center & Research Institute, USA

Abstract CV
14:00-14:30

Donor Lymphocyte Infusion Strategy: Korean Institutional Perspective

Silvia Park

College of Medicine, The Catholic University of Korea, Korea

Abstract CV

[SS08] Scientific Session 8: Advances in Pediatric Transplantation and Cellular Therapy September 12 (Fri), 13:00-14:30		Room B
Chair(s)	Hyeon Jin Park (National Cancer Center, Korea) Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea)

13:00-13:30

CAR T Cell Therapies for Pediatric Solid Tumors

Francesca Del Bufalo

IRCCS Bambino Gesù Children's Hospital, Italy

Abstract CV
13:30-14:00

The Optimal Conditioning for Allo-HSCT in Children with ALL (FORUM Trial)

Krzysztof Kalwak

Wroclaw Medical University, Poland

Abstract CV
14:00-14:30

Management of Post-HSCT Relapse in Pediatric Leukemia

Jae Won Yoo

College of Medicine, The Catholic University of Korea, Korea

Abstract CV

[NS01] Nursing Session 1: Multidisciplinary Approach to Treatment after Hematopoietic Stem Cell Transplantation l (KOR.) September 12 (Fri), 13:00-14:30		Room C
Chair(s)	EunJung Joo (National Cancer Center, Korea)

13:00-13:30

Optimizing Endocrine Outcomes after Hematopoietic Stem Cell Transplantation

Daham Kim

Yonsei University College of Medicine, Korea

Abstract CV
13:30-14:00

Acute Kidney Injury after Hematopoietic Stem Cell Transplantation

Junseok Jeon

Sungkyunkwan University School of Medicine, Korea

Abstract CV
14:00-14:30

Psychosocial Distress in Hematopoietic Stem Cell Transplantation

Eun-Seung Yu

The Cyber University of Korea, Korea

Abstract CV

[ES03] Education Session 3: Optimizing Outcomes in HSCT September 12 (Fri), 13:00-14:30		Room D
Chair(s)	Deog-Yeon Jo (Chungnam National University College of Medicine, Korea) Sung-Hyun Kim (Dong-A University College of Medicine, Korea)

13:00-13:30

Intensity of Conditioning Regimen (Evolution of Conditioning Regimen)

Yong Park

Korea University College of Medicine, Korea

Abstract CV
13:30-14:00

Advances in GVHD Prophylaxis: From ATG to Post-Transplant Cyclophosphamide (PTCy)

Joon Ho Moon

Kyungpook National University School of Medicine, Korea

CV
14:00-14:30

Second Malignancy after HSCT

Daehun Kwag

College of Medicine, The Catholic University of Korea, Korea

Abstract CV

[PS01] Presidential Symposium September 12 (Fri), 14:40-15:20		Room A
Chair(s)	Ho Joon Im (University of Ulsan College of Medicine, Korea)

14:40-15:20

AML-Specific Therapeutics: Integrating Risk-Stratified Transplantation and Immunotherapeutic Targeting

Soheil Meshinchi

Fred Hutchinson Cancer Center, USA

Abstract CV

[PL03] Plenary Session 3 September 12 (Fri), 15:20-16:00		Room A
Chair(s)	Seong Kyu Park (Soonchunhyang University College of Medicine, Korea)

15:20-16:00

Personalized Conditioning Strategies in Allogeneic HSCT: Balancing Disease Control and Toxicity Across Age Groups

Mohamad Mohty

Saint-Antoine Hospital, France

Abstract CV

[DS01] Debate Session 1: Splenectomy Prior to HSCT in Myelofibrosis: Necessity or Risk? September 12 (Fri), 16:40-18:20		Room A
Chair(s)	Sung Hwa Bae (Daegu Catholic University School of Medicine, Korea)

16:40-16:55

Necessity

Ik-Chan Song

Chungnam National University College of Medicine, Korea

Abstract CV
16:55-17:10

Risk

Yunsuk Choi

University of Ulsan College of Medicine, Korea

Abstract CV

[DS02] Debate Session 2: Donor Selection for HSCT in Pediatric Leukemia: Haploidentical versus Other Alternative Donor September 12 (Fri), 16:40-18:20		Room A
Chair(s)	Kyung-Nam Koh (University of Ulsan College of Medicine, Korea)

17:30-17:45

Haploidentical

Sung Han Kang

University of Ulsan College of Medicine, Korea

CV
17:45-18:00

Alternative Unrelated Donors (including Cord Blood)

Kyung Taek Hong

Seoul National University College of Medicine, Korea

Abstract CV

[JS04] Joint Symposium 4 (JSTCT-KSBMT): Transplant Strategies to Overcome MRD Positive Hematologic Malignancies September 12 (Fri), 16:40-18:20		Room C
Chair(s)	Seong Kyu Park (Soonchunhyang University College of Medicine, Korea) Takanori Teshima (Hokkaido University, Japan)

16:40-17:05

Defining MRD Response Through LSC Detection: A TIM-3–Based Flow Cytometric Perspective

Teppei Sakoda

Kyushu University Hospital, Japan

Abstract CV
17:05-17:30

Transplantation & Management of High-risk ALL with Poor MRD Response

Yu Akahoshi

National Cancer Center Hospital, Japan

Abstract CV
17:30-17:55

Integrating Flow Cytometry-Based MRD into Transplant and Maintenance Strategies in MM

Ari Ahn

College of Medicine, The Catholic University of Korea, Korea

Abstract CV
17:55-18:20

Transplantation & Management of High-risk MM with Poor MRD Response

Hyunsoo Cho

Seoul National University Hospital, Korea

CV

[ES04] Education Session 4: Infectious Complication September 12 (Fri), 16:40-18:10		Room D
Chair(s)	Jun Eun Park (Korea University College of Medicine, Korea) Jae-Yong Kwak (Jeonbuk National University Medical School, Korea)

16:40-17:10

Infection Prophylaxis in CAR T-Cell Therapy

Ji Hyun Lee

Dong-A University College of Medicine, Korea

Abstract CV
17:10-17:40

Should a Well-Cooked Diet Be Recommended for Transplant Patients?

Annalisa Paviglianiti

Hospital de la Santa Creu i Sant Pau, Spain

Abstract CV
17:40-18:10

Viral Infection after HSCT

Seung-Ji Kang

Chonnam National University Medical School, Korea

Abstract CV

Scientific Program